Skip directly to content

Pfizer Inc. and The Pfizer Foundation Pledge $40 Million to Help Combat COVID-19 Pandemic

09/04/20
 
The Pfizer Foundation this week announced that it had committed $40 million in medical and charitable cash grants to help combat the global health effects of the COVID-19 pandemic in the U.S. and around the world. 

 

The donation addresses the urgent needs of partners who are working to slow the spread of the virus within communities and strengthen vulnerable healthcare systems against future public health threats. Pfizer is also responding to patient and healthcare provider needs during this unprecedented time by evolving its U.S. Patient Assistance Program and donating additional critical medicines and vaccines in the U.S. and around the world. The combined donation includes medical and charitable grants from Pfizer Inc. and The Pfizer Foundation to support both U.S. and global responses to COVID-19 efforts. 

We are in the midst of a global health crisis and understand the need for immediate and significant philanthropic and private sector contributions to help sustain local and global partners on the front lines of the pandemic response, with the goal of saving lives.

At Pfizer, we believe it is our responsibility to help protect the most vulnerable from this disease and are putting the full weight of our resources behind our comprehensive COVID-19 response.” 

Caroline Roan, President, The Pfizer Foundation and Vice President, Global Health & Patient Access, Pfizer Inc.

The donation will support efforts within the U.S, but also internationally, with grant funding to international non-governmental organizations (INGOs) that support direct COVID-19 relief efforts. The majority of the donations will be distributed to partners within the next four to six weeks based on a previous evaluation of response priority needs and partner resource capabilities and gaps. 

These donations build on Pfizer’s longstanding commitments around the world to fight infectious disease, strengthen healthcare systems and reduce health disparities for patients in need, particularly in underserved communities.

This latest announcement follows hard on the heels of the COVID-19 Medical Service Program announced last week. The programme empowers medical colleagues to provide diagnostic, treatment and public health support in the battle against COVID-19 around the world. These activities complement the commendable volunteering efforts of many of Pfizer’s approximately 90,000 colleagues across the world who are donating their time and skills through virtual and other volunteer activities to help address urgent COVID-19 related health needs at the community level. 

 

Related articles:

 

Pfizer issues a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.

 

The companies have agreed to a letter of intent regarding the co-development and distribution of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection.

PP-PFE-GBR-2489 / April 2020